|
Severe Combined Immunodeficiency
|
0.620 |
GeneticVariation
|
disease |
BEFREE |
Homozygous mutations in CD3D and CD3E genes lead to a complete block in T-cell development and thus to an early-onset severe combined immunodeficiency phenotype.
|
16264327 |
2005 |
|
Severe Combined Immunodeficiency
|
0.620 |
Biomarker
|
disease |
BEFREE |
Our data provide important therapeutic proof of concept for future clinical applications of anti-CD3ε mAb treatment in severe combined immunodeficiency forms characterized by poor thymus function and autoimmunity.
|
22723555 |
2012 |
|
Immunologic Deficiency Syndromes
|
0.410 |
Biomarker
|
group |
BEFREE |
Identification of the transgenic integration site in immunodeficient tgε26 human CD3ε transgenic mice.
|
21203507 |
2010 |
|
Omenn Syndrome
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Here we show the effect of anti-CD3ε mAb administration in the RAG2(R229Q) mouse model, which closely recapitulates human OS.
|
22723555 |
2012 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Fc-modified anti-human CD3ε monoclonal antibodies (mAbs) are in clinical development for the treatment of autoimmune diseases.
|
23751612 |
2014 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Our data provide important therapeutic proof of concept for future clinical applications of anti-CD3ε mAb treatment in severe combined immunodeficiency forms characterized by poor thymus function and autoimmunity.
|
22723555 |
2012 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
A diallelic RFLP of the CD3-epsilon chain of the clonotypic T-lymphocyte receptor is not associated with certain autoimmune diseases.
|
1671848 |
1991 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We also investigated the therapeutic efficacy of these BsAbs in two mouse models: immunodeficient mice xenografted with patient-derived GD2<sup>+</sup> neuroblastoma or HER2<sup>+</sup> breast cancer, and human CD3ε transgenic mice implanted with a GD2<sup>+</sup> murine tumor.
|
31615814 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Immunocytometry studies (dual staining for CD3 epsilon and TfR) demonstrated that autologous T cells from the peripheral blood but not from the tumor expressed TfR following stimulation with IL2, anti-CD3 or PHA.
|
8050820 |
1994 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The anti-CD3ε antibody UCHT1 enhanced the <i>in vitro</i> tumor killing activity of human γδ T cells by an unknown molecular mechanism.
|
30038626 |
2018 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
NOD mice transgenic for the human CD3ε (also known as CD3E) chain (NOD-huCD3ε) were treated for recent-onset diabetes with oral givinostat, subtherapeutic doses of humanised CD3 antibodies (otelixizumab, 50 μg/day, 5 days, i.v.) or a combination of both drugs.
|
29030662 |
2018 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain.
|
27745778 |
2017 |
|
Diabetes Mellitus
|
0.020 |
Biomarker
|
group |
BEFREE |
Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain.
|
27745778 |
2017 |
|
Diabetes Mellitus
|
0.020 |
Biomarker
|
group |
BEFREE |
NOD mice transgenic for the human CD3ε (also known as CD3E) chain (NOD-huCD3ε) were treated for recent-onset diabetes with oral givinostat, subtherapeutic doses of humanised CD3 antibodies (otelixizumab, 50 μg/day, 5 days, i.v.) or a combination of both drugs.
|
29030662 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
While no association was found between this locus and type I diabetes, a significant difference in the frequency of the CD3 epsilon 8-kb allele was found between male and female patients (0.268 versus 0.430; P less than 0.0025, Pc = 0.02) and between female patients and healthy female controls (0.430 versus 0.267; P less than 0.015).
|
1671006 |
1991 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
To evaluate the bioactivity in vivo of IM-mAbs, APA spheres loaded with either anti-CD3ε or anti-CD95 mAb were incorporated into scaffolded islet implant (SI) test-beds and the SIs implanted into a mouse model of autoimmune (type 1) diabetes.
|
30274071 |
2018 |
|
Graft-vs-Host Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens.
|
11313428 |
2001 |
|
Graft-vs-Host Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In immunodeficient mice, anti-CD3ε PEBL-T cells had markedly reduced GVHD potential; when transduced with anti-CD19 CAR, these T cells killed engrafted leukemic cells.
|
29507075 |
2018 |
|
Aortic Valve Insufficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Absolute quantification with both PCR system showed significant higher mRNA levels of CD3ε and IP-10 in AR patients compared with stable transplants (STA), but there was no difference in 18S rRNA expression across the patient groups.
|
28654700 |
2017 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
We analyzed by functional flow cytometry the immune dynamics of primary and metastatic axillary nodes (mLN) in early breast cancers after exposure to T cell bispecific antibodies (TCB) bridging CD3ε and HER2 or CEACAM5, before and after chemotherapy.
|
30924846 |
2019 |
|
Celiac Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Refractory celiac sprue, a low-grade intraepithelial lymphoma characterized by expansion of clonal intraepithelial lymphocytes with intracellular CD3 epsilon but no surface CD3-T-cell receptor complexes, can be an intermediary step between celiac disease and overt T-cell lymphoma.
|
12851869 |
2003 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
IHC in a second cohort of EC (<i>N</i> = 93) were stained for IDO1, PD-L1, and CD3ε, followed by light microscopic analysis.
|
29805749 |
2018 |
|
HIV Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CD3ε Expression Defines Functionally Distinct Subsets of Vδ1 T Cells in Patients With Human Immunodeficiency Virus Infection.
|
29770136 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Female SLE (NZBWF1) and control (NZW) mice were administered either an antibody to CD3ε, a component of the T cell receptor complex expressed on all T cells, or IgG antibody (isotype control) for up to 4 weeks (intranasal; 25μg/week).
|
28400152 |
2017 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
To address these issues, we have demonstrated that chemically self-assembled nanorings (CSANs) displaying single chain antibodies can bind to both the CD3 ε subunit of the T-cell-receptor/CD3 complex and the CD22 antigen on malignant B cells such as B-leukemias or lymphomas.
|
26230248 |
2015 |